Article
Neoadjuvant combo efficacious in high-risk prostate cancer
One-third of men with high-risk prostate cancer achieved pathologic complete response (pCR) or near-complete response to 6 months of preoperative therapy with abiraterone acetate (ZYTIGA), leuprolide, and prednisone, investigators reported at the American Society of Clinical Oncology annual meeting in Chicago.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Related Content
